share_log

Oppenheimer Maintains Outperform on ResMed, Lowers Price Target to $200

Benzinga ·  Apr 26 13:55

Oppenheimer analyst Suraj Kalia maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $205 to $200.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment